Compounded Methylene Blue

Methylene blue is a synthetic phenothiazine compound used in medicine since the 1890s. At high IV doses it is FDA-approved to treat methemoglobinemia, a blood-oxygen disorder. At low oral doses (typically 5–50 mg/day), it acts as an alternative electron carrier inside mitochondria — accepting electrons from NADH and FADH2 and donating them to cytochrome c. This bypasses bottlenecks at Complex I and III, supports ATP production, and reduces the reactive oxygen species generated when the electron transport chain backs up.

The FDA-approved use is intravenous methylene blue at 1–2 mg/kg for methemoglobinemia — a hospital intervention. Low-dose oral methylene blue (5–50 mg/day) is a fundamentally different protocol used off-label for cognitive and mitochondrial support. The dose-response curve is biphasic: low doses act as an electron carrier and antioxidant, while high doses can become pro-oxidant and act as a strong MAOI. Staying in the low-dose range is what makes the protocol tolerable and safe for daily use.

Yes — blue-green urine is the most reliable, immediate, and entirely harmless effect of methylene blue. It happens because the dye is excreted unchanged by the kidneys. Your tongue may also temporarily stain blue-green if you take the oral solution. Both effects fade within a day or two of stopping the medication and are not a sign of toxicity.

No. Methylene blue is a potent monoamine oxidase inhibitor (MAOI), particularly at higher doses. Combining it with SSRIs, SNRIs, MAOIs, tricyclics, MDMA, or other serotonergic agents can trigger serotonin syndrome — a medical emergency. Your prescribing doctor reviews your full medication list (including supplements like St. John’s wort, 5-HTP, and tryptophan) before issuing a prescription, and methylene blue will not be prescribed if you are on a serotonergic agent.

Many patients report subjective changes in mental clarity, focus, or daily energy within the first 1–2 weeks of consistent dosing. Mood and stamina effects in the published low-dose literature typically appear within 4–8 weeks. Methylene blue is not cumulative in the way peptides are — the half-life is short — so the daily dose is what produces the day-to-day effect.

Methylene blue has more than a century of pharmacological history, and low-dose oral protocols have been used in cognitive and mood research for decades without evidence of cumulative toxicity in screened patients. Standard long-term safety practice includes cycling (5 days on / 2 off, or 8 weeks on / 2 off), staying within the low-dose range, periodic check-ins with your prescribing doctor, and keeping your medication list current so any new serotonergic prescription can be flagged before it is started.

Yes — methylene blue is commonly stacked with NAD+ and glutathione because the three target different parts of the same cellular-energy and antioxidant system. NAD+ supports the substrate side of mitochondrial metabolism, glutathione supports phase II detoxification and antioxidant capacity, and methylene blue acts directly inside the electron transport chain. Combinations should always be doctor-supervised and adjusted based on how you respond.

Peptide12 partners with state-licensed compounding pharmacies that hold state and federal licensure and undergo regular USP <795> non-sterile compounding audits. Methylene blue is compounded from pharmaceutical-grade USP active pharmaceutical ingredient — not from aquarium-grade or industrial dye sources, which can contain heavy-metal contaminants. Every batch is third-party tested for identity, potency, and purity. Compounded oral methylene blue is not FDA-approved as a finished drug product but is prepared from FDA-regulated active ingredient under individualized prescription.